![]() ![]() ![]() ![]() We are encouraged by these early results and look forward to reporting additional data from the multiple ascending dose portion of the study later this year,” he added. Additionally, we believe the short pharmacokinetic profile of AZP-3601 will maintain bone mass and integrity, a key benefit since the majority of patients with hypoparathyroidism are middle-aged women at risk of osteoporosis. We believe that this pharmacological profile is ideally suited to fulfill the clinical needs of patients with hypoparathyroidism, including symptom management and prevention of kidney disease. “By targeting a specific conformation of the PTH1 receptor, these data demonstrate a prolonged serum calcium response, despite AZP-3601 having a very short half-life. “We are delighted with this first set of clinical data highlighting AZP-3601’s unique mechanism of action,” said Thierry Abribat, Ph.D., founder and chief executive officer of Amolyt Pharma. The data were presented as a virtual poster at the Endocrine Society’s Annual Meeting (ENDO 2021). The data demonstrated a significant, sustained increase in blood calcium levels for at least 24 hours following a single administration of AZP-3601. LYON, France and NEWTON, Mass., Ma(GLOBE NEWSWIRE) - Amolyt Pharma today presented positive data from the first cohorts of the single ascending dose portion of its Phase 1 clinical trial in healthy volunteers evaluating the company’s lead clinical candidate, AZP-3601, for the treatment of hypoparathyroidism. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |